Merck Wins Chance for Royalties on Gilead’s Hepatitis C Cure
- Merck seeks royalty saying it paved way for liver remedy
- Gilead dominates market with $20 billion U.S. sales since 2013
This article is for subscribers only.
Merck & Co. won a sweeping jury verdict that allows it to seek royalties from Gilead Sciences Inc. for the drugs that have dominated the hepatitis C market with $20 billion in U.S. sales since 2013.
Jurors Tuesday embraced Merck’s claims that its scientists were responsible for early breakthroughs that led to the development of the Sovaldi and Harvoni medicines that propelled Gilead to become the world’s largest biotechnology firm by market valuation.